Trend

An official statement released by the American Gaming Association (AGA) and partner Reed Exhibitions has announced the cancellation of this year’s Global Gaming Expo (G2E), at least as a ‘in-person’ event. As a result of the continuing devastation arising from the COVID-19 pandemic, the suspension, which comes after 20 years of activity, was put directly on the organisers. G2E was expected to take place from 5 to 8 October 2020 but will now be held at the Sands Expo and Convention Center from 4 to 7 October 2021. Bill Miller, the President and CEO of AGA explained: “In light of continued uncertainty around a viable marketplace at a physical G2E show, global travel restrictions, and currently unknown guidance on large public gatherings this fall, we have come to the unfortunate conclusion that we simply cannot hold an in-person G2E this year.” However, the organisers said they are committed to promoting cultural , educational and networking opportunities for the global gaming ...

Incyte  said on Friday an independent committee concluded that its drug for a type of skin cancer in combination with  Merck 's Keytruda failed to meet the main goal in a late-stage study. Incyte shares fell 20 percent in premarket trading Friday, while Merck shares were down about 2 percent. The two companies would stop the study as it did not meet the primary goal of improving progression-free survival compared to patients on Keytruda monotherapy. Merck's Keytruda is approved for the treating several forms of cancer, including lung cancer and advanced melanoma. The companies said the study's second main goal of overall survival was also not expected to reach a statistical significance. The study was evaluating a combination of Incyte's inhibitor Epacadostat and Merck's Keytruda for the treatment of metastatic melanoma. Incyte  said on Friday an independent committee concluded that its drug for a type of skin cancer in combination with  Merck ...